Inga Peters (@IngaPeters2017) header
Inga Peters (@IngaPeters2017) profile picture

Inga Peters

@IngaPeters2017

Head of Urology @Krankenhaus Nordwest / Frankfurt Main Professor of Urology and Researcher

Joined February 2017
  • Tweets192
  • Following123
  • Followers124
1Media
Photo by Inga Peters (@IngaPeters2017)
Inga Peters retweeted
Muhammad Ali (@dr_alimuhammad) profile picture
Muhammad Ali
@dr_alimuhammadJun 2
Kidney SABR on the front cover of @TheLancetOncol. A well-deserved recognition for @_ShankarSiva for his work and efforts over the past 10+ years. thelancet.com/journals/lanon…
Image from Muhammad Ali (@dr_alimuhammad)
2
37
7
98
40,026
JUST IN (and finally...): Pembrolizumab hits OVERALL SURVIVAL in KYN-564 adjuvant study in Kidney Cancer!!! The time has finally come... via @BusinessWire @DanaFarber_GU @tompowles1 @OncoAlert @OncBrothers @OncLive @TargetedOnc @urotoday @Uromigos @ALLIANCE_org @eaonc @SWOG businesswire.com/news/home/2…
Image from Toni Choueiri, MD (@DrChoueiri)
13
169
27
482
86,617
Replying to @BenjaminPradere
@BenjaminPradere and Arlene Siefker-Radtke on phase 2 #NORSE and phase 3 #THOR study results with #erdafitinib in metastatic #UrothelialCancer 👉@Uroweb podcast: uroweb.org/education-events/…

Dr. Siefker-Radtke discusses new mUC study results - Norse and THOR - Uroweb

In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Dr. Arlene O. Siefker-Radtke (US) from the Depart. of Genitourinary Medical Oncology, The University of Texas MD Anderson...

uroweb.org
European Association of Urology (EAU) (@Uroweb) profile pictureEuropean Association of Urology (EAU)@Uroweb12 Jun 2023
Dr. Siefker-Radtke reveals promising details from 2 #mUC studies in a 🆕 #EAUpodcast with @BenjaminPradere at #ASCO23. ➡️Norse: erdafitinib (45% RR) vs erdafitinib + cetrelimab (55% RR) ➡️THOR: erda OS benefits compared to chemotherapy 🎧Learn more 👇 ow.ly/8hv150OLx0q
Image from European Association of Urology (EAU) (@Uroweb)
5
9
1,944
Inga Peters retweeted
Allen Edel (@TallAllen) profile picture
Allen Edel@TallAllen14 Feb 2023
Yet another trial of focal thermoablation, cryo, proving substandard results - 35% still had csPCa (only 46% had no PCa, and that neither MRI nor PSA were good indicators. Why is there no biochemical analysis to explain it? @BehfarEdhaie onlinelibrary.wiley.com/doi/…
Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes

Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes

In the near to intermediate term, partial gland ablation with focal cryotherapy was found to be a moderately effective and relatively safe treatment for men with intermediate risk prostate cancer....

onlinelibrary.wiley.com
4
9
1
20
16,592
Replying to @ASCO
@ASCO #GU23 Abs#18👉 bit.ly/3E65gfs by @AlanBryce9 et al 👉Rucaparib significantly improved rPFS vs either docetaxel or abi/enza in BRCA/ATM + mCRPC #prostatecancer. OS trending favorably in BRCA+pts @kalasri3 @oncoalert @urotoday @PCF_Science @uromigos – at Holladay, UT
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
2
32
4
55
12,912
#Operieren in der #Schwangerschaft ist möglich! Dennoch wird es schwangeren Chirurginnen auch heutzutage immer noch in vielen Kliniken schwer gemacht. Das führt zu Verzögerungen in der operativen Ausbildung und stellt für viele Frauen einen unnötigen Karrierenachteil dar.
1
4
6
747
5/ IL-15 superagonist NAI can induce persistent CR in 71% of BCG-unresponsive #NMIBC with #CIS + 89% avoided cystectomy and 100% DSS at 2 years. @UroCancerMD @UclaUrology @drpatrick @NEJMEvidence evidence.nejm.org/doi/full/1…
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
2
8
1
35
6,845
1/ #ARASENS phase 3 trial shows ⬆️OS with darolutamide in combination with docetaxel and ADT in #mHSPC (vs docetaxel + ADT alone) with similar AE profile, leading to @US_FDA approval. #MatthewSmith @BertrandTOMBAL @MGHMedicine @NEJM nejm.org/doi/full/10.1056/NE…
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
Image from Toni Choueiri, MD (@DrChoueiri)
2
22
1
65
13,748
#Frailty assessment has clinical utility in cancer treatment. Analyses of #pazopanib vs. chemo in sarcoma pts.: 👉#geriatric & functional assessment - more important than age 👉both associate with oncological outcomes and tolerability sciencedirect.com/science/ar…
Image from Viktor Grünwald (@ViktorGruenwald)
6
19
2,909
Breaking news: Phase 3 randomized TALAPRO-2 trial of Enza + Talazoparib vs. Enza meets primary endpoint in the 1st line mCRPC #ProstateCancer in both HRR+ and HRR- patients (study design👇).Press release 👉 bit.ly/3SSjJAp @OncoAlert @urotoday @Huntsman_GU @PCF_Science
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
15
131
13
271
Just In @KCA_Journal :👉Excellent commentary on the evaluation of the optimal duration of Immunotherapy in #kidneycancer by Dr. Mamta Parikh & @PrimoLaraMD @UCD_Cancer 👉Need for prospective clinical trials👉bit.ly/3S16wFL @Oncoalert @KidneyCancer @SWOG
Image from Kidney Cancer (@KCA_Journal)
1
26
48
Inga Peters retweeted
Hannes Cash (@CashHannes) profile picture
Hannes Cash@CashHannes21 Sep 2022
Data from the Foxpro Trial on ultra focal therapy presented by @HardenbergJost @dgukongress focal therapy session. Critical discussion. Ultra focal Not the way to go @martin_schostak @IngaPeters2017 @JPRadtke
Image from Hannes Cash (@CashHannes)
Image from Hannes Cash (@CashHannes)
Image from Hannes Cash (@CashHannes)
Image from Hannes Cash (@CashHannes)
4
1
9
Just in @CCR_AACR: Happy to report👉SPOP mutation as 1st treatment selection biomarker in mCSPC #ProstateCancer , predicts response to ARAT & not to docetaxel bit.ly/3U1d88k @neerajaiims @EAntonarakis @RyonGraff @geoff_oxnard @OncoAlert @PCF_Science Tweetorial (1/10)
Image from Umang Swami, MD, MSCI, FASCO (@umangtalking)
Image from Umang Swami, MD, MSCI, FASCO (@umangtalking)
Image from Umang Swami, MD, MSCI, FASCO (@umangtalking)
14
100
12
285
Inga Peters retweeted
Tom Powles (@tompowles1) profile picture
Tom Powles
@tompowles118 Jul 2022
ctDNA (Natera) extending is role into adjuvant bladder cancer with Medicare coverage. ctDNA identifies a high risk group . The R3 (011) trial will validate the role of atezolizumab in this setting. Recruitment and sites needed prnewswire.com/news-releases… @NateraGenetics
Image from Tom Powles (@tompowles1)
Image from Tom Powles (@tompowles1)
33
1
78
Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men pubs.rsna.org/doi/10.1148/ra… #ProstateCancer #medtwitter #CancerResearch
Image from Baris Turkbey MD (@radiolobt)
Image from Baris Turkbey MD (@radiolobt)
Image from Baris Turkbey MD (@radiolobt)
Image from Baris Turkbey MD (@radiolobt)
1
12
39
Tamsulosin facilitates passage of renal stones after ESWL . #ESWL #Urolithiasis #urology A randomized trial of adjuvant tamsulosin as a medical expulsive therapy for renal stones after shock wave lithotri… pubmed.ncbi.nlm.nih.gov/3557…
A randomized trial of adjuvant tamsulosin as a medical expulsive therapy for renal stones after...

A randomized trial of adjuvant tamsulosin as a medical expulsive therapy for renal stones after...

Adjuvant medical expulsive therapy (MET) for shock wave lithotripsy (SWL) is controversial. With limited use of the computed tomography (CT), the stone free rate (SFR) become overestimated. Herein we...

pubmed.ncbi.nlm.nih.gov
1
1
4
Whilst PROMS score summaries are important, and shown in the PROTECT NEJM QoL paper, these data present the very significant side effects from radical therapy in a manner that is more easily understood by patients (and me).
Drew Moghanaki (@DrewMoghanaki) profile pictureDrew Moghanaki
@DrewMoghanaki4 May 2022
The ProtecT team releases another analysis that shows what happened to 2,565 men with prostate cancer who were randomly assigned to receive surgery, radiation therapy, or active monitoring. #pcsm #radonc @QuinteTBristol
Image from Drew Moghanaki (@DrewMoghanaki)
6
14
PD-L1 is a very unreliable biomarker in RCC as it is in bladder cancer. We can and must do better to find predictive tools.
Francesco Massari (@fmassari79) profile pictureFrancesco Massari@fmassari7913 Apr 2022
The limited role of PD-L1 as predictive biomarkers in mRCC ⁦@fsgimt⁩
Image from Francesco Massari (@fmassari79)
Image from Francesco Massari (@fmassari79)
Image from Francesco Massari (@fmassari79)
15
1
53
Sarcomatoid histology a good biomarker associated with greater benefit to adjuvant Pembro in RCC.
Image from Brian Rini, MD (@brian_rini)
25
1
104
Malignancy risk stratification of cystic renal lesions based on a contrast-enhanced CT-based machine learning model and a clinical decision algorithm link.springer.com/article/10… #radiomics #CancerResearch #MedTwitter
Image from Baris Turkbey MD (@radiolobt)
Image from Baris Turkbey MD (@radiolobt)
Image from Baris Turkbey MD (@radiolobt)
4
12
Load more